ASCO GI: Modest Gain With Avastin for Advanced Colorectal Cancer
January 22nd 2007ORLANDO -- Avastin (bevacizumab) added to an Eloxatin (oxaliplatin)-based chemotherapy regimen modestly extended progression-free survival in metastatic colorectal cancer, according to results of a randomized phase III trial.
ASCO GI: When Oncologists Say Risk, Patients Hear Benefit
January 22nd 2007ORLANDO -- More that a third of colorectal cancer survivors surveyed said they would be willing to undergo a repeat course of highly toxic therapy for even a minuscule reduction in the risk of recurrence, researchers reported here.
ASCO: GI Single-Agent Chemotherapy Improves Gastric Cancer Survival
January 19th 2007ORLANDO -- Adjuvant chemotherapy with S-1, an oral prodrug of 5-fluorouracil (5-FU), improved survival compared with surgery alone, according to results of a phase III trial of 1,059 gastric cancer patients here reported here.